NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2018.60 1.80 (0.09%)

58.26% Gain from 52W Low

660.6K NSE+BSE Volume

NSE 24 Sep, 2025 3:31 PM (IST)

56,965.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Glenmark Pharmaceuticals Ltd. is on 26 Sep 2025 for the purpose of Interim Dividend See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

29 Jan 2016

2018.60

0.09%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

ICICI Securities Limited

Glenmark Pharmaceuticals Ltd. has gained 33.26% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

02 Jan 2016

2018.60

0.09%

Glenmark Pharmaceuticals Ltd: Diversified Portfolio to Sustain Momentum (Jan 02, 2016)

Buy: Glenmark Pharmaceuticals Ltd.

Karvy

US-Big opportunities ahead: USFDA approval for Glenmark generics hasslowed from 18 in FY11 to 6 in FY15 even as 37 plain filings are pending forapproval for Glenmark. The improved approval rate (8 in H1-FY16) should sustain regular growth while incrementally gZetia (with 180 day exclusivity), gZyvox and gVoricanozole should support an 18% CAGR US formulations growth in FY15-18E.

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

30 Oct 2015

2018.60

0.09%

Glenmark 30Oct2015

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

9 US sales saw steady yoy growth of 10% despite 57% price erosion in base portfolio; GNPguidesforstrongH2ledbypickupinrecent/newlaunches Domesticformulationswereaheadofexpectationswith27%yoyimprovementdueto...

Glenmark Pharmaceuticals Ltd. has gained 33.26% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

30 Oct 2015

2018.60

0.09%

Glenmark Pharma - 2QFY16 Result Update

Buy: Glenmark Pharmaceuticals Ltd.

Target

Reliance Securities

ff Management expects slowdown in Venezuela as it is hard to obtain the requisite import license. Potential threat of significant devaluation in Venezuela puts US$2030mn of company's exposure there at risk. As per our estimates, Venezuela contributed ~6% of FY15 profits. Factoring in the devaluation in FY17E, we...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

03 Aug 2015

2018.60

0.09%

Glenmark 3Aug2015

Neutral: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Phillip Capital

company maintained its sales growth guidance of 1820% and EBITDA of ~Rs 17.5bn (implying ~22% margin) on a presumed ramp up in US generic sales and continued momentum in domestic formulations. However, modest US sales growth (8.5%) in Q1...

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf